DRI provides innovative capital solutions to a range of inventors, academic and research institutions and life sciences companies either through the purchase of existing royalties created by licensing activities, or creating synthetic royalties in directly negotiated transactions
Each of these parties have different motivations for monetizing their royalty entitlements:
Typically seeking to mitigate risk because their royalty entitlement often makes up a substantial portion of their net worth. They also sell royalties to accelerate cash flows for estate planning purposes or to pursue personal endeavors such as philanthropy.
ACADEMIC AND RESEARCH INSTITUTIONS
Often monetize royalty streams to mitigate risk, to generate funds that can be re-invested in research, to fund capital projects or to remove perceived conflicts.
LIFE SCIENCE COMPANIES
View royalty monetization and revenue interest transactions as an attractive financing alternative to support the companies’ research and development efforts, to bridge cash flow needs, and to accelerate the recognition of royalty revenues.